Podcasts about etoposide

Diana Ash had suffered from irritable bowel syndrome much of her life, but in 2019, she believed the IBS symptoms she felt were something altogether different.  Her concerns were proven correct when an ultrasound indicated a mass near her abdomen the size of a “mini football.”  Not long after that, she was diagnosed with Stage 1C Ovarian Cancer.  Diana underwent an oophorectomy, a surgical procedure that successfully removed one ovary and one fallopian tube.  After the surgery, she had to undergo BEP chemotherapy, an extremely aggressive regimen.  However, she achieved survivorship and has written a book about her experience.   Diana Ash led an active lifestyle in her hometown of Ottawa, Ontario, Canada.  She enjoyed hiking, running and diving; but ever since she was a small child, Diana dealt with irritable bowel syndrome.  In 2019, in addition to IBS' typical symptoms, she experienced fatigue and loss of appetite.  When she sought medical attention, she was told her problem was IBS and nothing more.  To Diana, that was not a satisfactory response.   She insisted on blood work and an ultrasound.  The latter revealed a mass near her abdomen.  It measured 10 X 16 cm, or as she said, “the size of a mini football.” Diana pressed doctors for more information and accurate information, and she was eventually diagnosed with Stage 1C ovarian cancer.  She was shocked with the diagnosis, but relieved that her cancer had been caught at an early stage, which is not typical for those diagnosed with ovarian cancer.   Diana underwent an oophorectomy, a surgical procedure which removed one of her ovaries and one of her fallopian tubes.  The surgery was a success, but her surgeon said the procedure was the easy part of her treatment.  Next up was an extremely aggressive chemotherapy regimen.  BEP chemotherapy includes cisplatin, bleomycin and etoposide.  Diana experienced the usual side effects, but was even more difficult was her being told that she would no longer be able to run or dive.   There was also the matter of childbearing.  She received a Lupron injection, which meant she had to deal with its side effects while dealing with the side effects from her chemo regimen.  She was eventually able to freeze some of her eggs, which will enable her to have kids.   Diana Ash achieved survivorship and wants to help others diagnosed with cancer.  Fueled by a message emphasizing optimism and self-advocacy, she wrote “Take Back The Power,” available on Amazon.  The book was written in English, but as a bilingual Canadian, she hopes to one day translate the book into French.   Additional Resources:   Diana's Book: “Take Back The Power,” a guide for young women with cancer      

In this week's episode we'll discuss PAR2-biased signaling in thrombo-inflammation. Then, we'll learn about how hemoglobin levels are linked to survival in transfusion-dependent beta-thalassemia. Finally we'll hear about how etoposide is better than its reputation in primary HLH—hemophagocytic lymphohistiocytosis. Symptomatic patients treated with etoposide have substantially better outcomes as compared to the historical experience.

BUFFALO, NY- September 20, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 17, entitled, “Development of a DNA damage-induced senescence model in osteoarthritic chondrocytes.” Senescent cells (SnCs) have been described to accumulate in osteoarthritis (OA) joint tissues in response to injury, thereby participating in OA development and progression. However, clinical therapeutic approaches targeting SnCs using senolysis, although promising in preclinical OA models, have not yet proven their efficacy in patients with knee OA. This pitfall may be due to the lack of understanding of the mechanisms underlying chondrocyte senescence. In their new study, researchers Mélina Georget, Anaïs Defois, Romain Guiho, Nina Bon, Sophie Allain, Cécile Boyer, Boris Halgand, Denis Waast, Gaël Grimandi, Alban Fouasson-Chailloux, Jérôme Guicheux, and Claire Vinatier from Nantes Université aimed to generate models of chondrocyte senescence. “In this context, our study aims to develop in vitro models of chondrocyte senescence by investigating the ability of etoposide and IL-1β treatments to produce a reliable chondrocyte senescent model.” This study used etoposide, to induce DNA damage-related senescence or chronic exposure to IL-1β to entail inflammation-related senescence in human OA chondrocytes. Several hallmarks of cellular senescence, such as cell cycle arrest, expression of cyclin-dependent kinase inhibitors, DNA damages, and senescence-associated secretory profile were evaluated. Chronic exposure to IL-1β induces only partial expression of senescence markers and does not allow us to conclude on its ability to induce senescence in chondrocytes. On the other hand, etoposide treatment reliably induces DNA damage-related senescence in human articular chondrocytes evidenced by loss of proliferative capacity, DNA damage accumulation, and expression of some SASP components. “Etoposide-induced senescence model may help investigate the initiation of cellular senescence in chondrocytes, and provide a useful model to develop therapeutic approaches to target senescence in OA.” DOI - https://doi.org/10.18632/aging.204881 Corresponding author - Claire Vinatier - claire.vinatier@univ-nantes.fr Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204881 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, senescence, osteoarthritis, etoposide, chondrocytes About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

When 17-year-old Asa Newell felt acute pain in a testicle, pain that reached around to his back, first he hesitated, but then he went to get it checked out.  It didn't take a doctor long to determine that Asa had testicular cancer.  Asa wanted to minimize or eliminate the possibility of it spreading or returning, so he chose an aggressive, chemotherapy-based treatment regimen.  That, along with a positive attitude resulted in survivorship.

Após mais de três décadas de pouca evolução em relação ao tratamento do câncer de pulmão de pequenas células (CPPC), o surgimento e desenvolvimento de imunoterapia, baseadas em inibidores de checkpoint, em particular dos anti PD-L1, durvalumabe e atezolizumabe, forneceram melhorias significativas em termos de Sobrevida Global para tais pacientes com doença avançada. Além disso, o tratamento com essa terapia, vem conseguindo um benefício de sobrevida mais duradouro, o que é impressionante! Entretanto, como os trabalhos de imunoterapia em paciente com CPPC são relativamente recentes, ainda não está claro se o ganho de sobrevida a longo prazo vai permanecer nesse cenário.Neste episódio, o Dr. Luiz Fernando Araújo (DASA Oncologia), juntamente com a Dra. Clarissa Baldotto (Oncologia D'Or) discutem os resultados a longo prazo (após 3 anos de seguimento) do CASPIAN. Este foi um grande estudo fase III que avaliou o tratamento com durvalumabe como primeira linha, com ou sem tremelimumabe, em combinação com etoposide + cisplatina ou carboplatina em pacientes com CPPC.Com mais de 800 pacientes randomizados, esse tempo de seguimento (mediana de 39,4 meses, maturidade de 86%), continuou a mostrara a manutenção de ganho de sobrevida com Hazard Ratio de 0,71 com o durvalumabe isolado; A SG mediana foi de 12,9 versus 10,5 meses, e a taxa de SG em 36 meses foi de 17,6% versus 5,8%.Sejam bem vindos a mais um episódio do Clinical Papers Podcast!Para saber mais sobre o paper acesse: https://www.esmoopen.com/article/S2059-7029(22)00029-1/fulltextEste episódio teve o apoio da AstraZeneca

In this week's episode, we review results of a randomized, placebo-controlled phase 3 trial demonstrating that targeted inhibition of C1s with the monoclonal antibody sutimlimab is effective and well tolerated in non-transfusion-dependent patients with cold agglutinin disease. We'll also review a population-based study evaluating the impact of adding either etoposide or autologous stem cell transplantation to CHOP in young and fit patients with peripheral T cell lymphomas. Finally, we'll review a paper that elucidates a mechanism of lung injury in sickle cell disease. It involves gasdermin-D-dependent production of neutrophil extracellular traps in the liver, which travel intravascularly to the lung, where they promote occlusion of the pulmonary microcirculation.

A type of mental fog—known as “chemo brain”—is widely experienced by patients who have undergone cancer treatment. Cancer research institutions define chemo brain as impaired cognition, including cloudiness, memory loss and/or lack of concentration, that occurs before, during and/or after cancer treatment. This condition can negatively impact quality of life in a significant way. Chemo brain not only affects recovering individuals but also their loved ones, who often must take on additional caregiving responsibilities. Despite the name, chemotherapeutic drugs may not be the only treatments responsible for chemo brain. A chemotherapy protective drug called amifostine is commonly used in patients and paired with chemotherapeutic agents. Amifostine functions to protect healthy cells from DNA double strand breaks (DSBs) induced by chemotherapy. Another commonly prescribed cancer treatment is called etoposide, which is a chemotherapeutic drug that also targets DSBs. Etoposide, on the other hand, functions to increase DSBs in cancer cells. Recently, researchers have suggested that DSBs could play a role in learning, memory and immediate early gene (IEG) expression. The activity of IEGs can be used to identify neural circuits involved in learning and memory processes. “Despite their wide clinical use, there is little information about how amifostine and etoposide affect learning and memory.” Researchers from Oregon Health and Science University conducted a novel study to observe the isolated effects of these common DSB-altering agents on learning, memory and IEG expression. Systemic injections of amifostine and etoposide were examined in both male and female mice. Their research paper was published by Oncotarget in January of 2022, and entitled, “Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner.” Full blog - https://www.oncotarget.org/2022/01/28/trending-with-impact-what-causes-chemo-brain/ DOI - https://doi.org/10.18632/oncotarget.28180 Correspondence to - Jacob Raber - raberj@ohsu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28180 Keywords - amifostine, etoposide, double strand breaks, memory, sex About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

ONS member Cindy Dionysus, MSN, RN, OCN®, infusion nurse at Riverwood Healthcare Center in Aitkin, MN, and nursing instructor at Central Lake College in Brainerd, MN, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how oncology nurses can safely administer etoposide chemotherapy and manage its associated adverse events. This episode is part of an ongoing series about outpatient oncology drug infusion. The others are linked in the episode notes. The advertising messages in this episode are paid for by i3 Health.  Episode Notes  Check out these resources from today's episode:  NCPD contact hours are not available for this episode.  Previous Oncology Nursing Podcast episodes on outpatient oncology drug infusion  Oncology Nursing Podcast Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments  Oncology Nursing Podcast Episode 162: What Nurses Need to Know About Central Lines and Ports  Clinical Journal of Oncology Nursing article: Venous Flare Reactions: A Case Report of Reactions Following Etoposide Infusion  ONS course: Fundamentals of Chemotherapy Immunotherapy Administration  ONS course: ONS/ONCC Chemotherapy Immunotherapy Certificate Course  ONS position statement: Education of the Registered Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies American Cancer Society patient resources on chemotherapy treatment Etoposide package insert  National Cancer Institute information on etoposide National Comprehensive Cancer Network guidelines with evidence blocks National Institute for Occupational Safety and Health: Hazardous Drugs in Healthcare Settings  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To provide feedback or otherwise reach ONS about the podcast, email  pubONSVoice@ons.org.

This episode covers etoposide!

This week, we'll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we'll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we'll summarize some recent FDA approvals and announcements.Coverage of stories discussed this week on ascopost.com:CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLCColorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years OldAmerican College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 YearsFDA Approves Pegfilgrastim BiosimilarFDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian CancerFDA Approves Daratumumab Combination for Transplant-Eligible Patients With Multiple MyelomaStephen Hahn, MD, to Be Nominated FDA Commissioner

Our Foundations in #OncoPharm returns with etoposide, including a deeper than necessary discussion of the historical medical(?) uses of podophyllotoxins, its MOA, uses, and toxicities.

Stefan K. Barta, MD, of the University of Pennsylvania, joins David Henry, MD, to discuss the treatment and diagnosis of lymphoma in patients with HIV.    In this week's Clinical Correlation, Ilana Yurkiewicz, MD, has Part 2 of her discussion on informed consent in cancer. Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford University and is also a columnist for Hematology News. More from Dr. Yurkiewicz here. Notes, Transcripts, Links  Show notes By Emily Bryer, DO Resident in the department of internal medicine, University of Pennsylvania.  Immunosuppression in patients with HIV, especially with low CD4 counts, is associated with the development of lymphomas.  Diffuse large B-cell lymphoma is the most common lymphoma in patients with HIV followed by Burkitt lymphoma and Hodgkin lymphoma.  Extra-nodal manifestations of lymphoma are more common in patients with HIV, especially with lower CD4 counts. Following pathologic diagnosis, staging of lymphoma should include: CT scan PET scan Evaluation of CNS (MRI brain and LP) Bone marrow biopsy Evaluation for hepatitis B and C co-infection. Fluorescence in situ hybridization (FISH) is a molecular technique that identifies portions of DNA and helps to identify translocations and rearrangements. cMYC, BCL2, and BCL6 are all pro-proliferative genes and commonly implicated in lymphoma. cMYC rearrangement pose higher risk of CNS involvement and CNS relapse.  cMYC rearrangement (as opposed to cMYC translocation) requires therapy that is more aggressive therapy than R-CHOP.  Treatment of high grade diffuse large B-cell lymphoma: R-EPOCH Ibrutinib plus R-EPOCH Resources/Links: AIDS Malignancy Consortium Blood. 2004;103:275-82. Blood. 2010 Apr 15; 115(15): 3008-16. Clinical Trial: NCT03220022  Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas  

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.

Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.

Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.

Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Response after early chemotherapy cycles might identify patients who could safely forgo consolidation with radiotherapy.

Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.

Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.

Background: Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy. We report phase II data of highdose chemotherapy and peripheral blood stem cell (PBSC) rescue in patients with MSTS responding to AI-G chemotherapy. Patients and Methods: From 1997 to 2002, 55 patients with MSTS were prospectively treated with 4 cycles of AI-G (doxorubicin 75 mg/m(2), ifosfamide 6 g/m(2) with G-CSF support). Responders received 2 further cycles of AI-G with collection of PBSCs. High-dose chemotherapy consisted of ifosfamide 12 g/m(2), carboplatin 1.2 g/m(2) and etoposide 1.2 g/m(2) (HD-ICE) followed by reinfusion of PBSCs. Results: Twenty-one of 55 patients (38%) were assessed as responders (3 complete response, 18 partial response). All but 2 patients refusing treatment received high-dose chemotherapy with PBSC rescue leading to grade IV hematologic toxicity without severe infections in all patients. No toxic death occurred. After a median follow-up time of 30 months, the median progression-free time was 12 months and survival time was 22 months for the entire group. By intent-totreat analysis the probability of 5-year progression-free survival was significantly higher for patients allocated to HD-ICE compared to patients receiving second-line chemotherapy after failure of AI-G (14 vs. 3%; p = 0.003). The estimated 5-year overall survival between the 2 groups was different (27% vs. not reached) but did not reach significance (p = 0.08). Conclusion: HD-ICE is feasible and promising in patients with chemosensitive MSTS. A randomized phase III trial is warranted to further define the role of HD-ICE as consolidation treatment in these patients.